Bronchial Asthma in the Era of COVID-19

Coronavirus disease also (COVID 19) a worldwide pandemic contagious infection produced through the Coronavirus SAR.S-CoV2, and aberrant, overactive immunity and "chemokines" have been hypothesized as possible pathogenic reasons for rapid COVID 19 development. Because of a poor viral immunogenic reaction with a potential for aggravation evoked by groups of similar respiratory virus, asthmatic patients have increased susceptibility to and severe forms of covid infection. Existing research, however, has not found an anticipated proportion of patients with asthma between COVID patient. Features of the immune responses of type2 nature, such as type2 cytokines such as IL-4, IL-13 and eosinophil buildup, may give protection against the Corona virus. Furthermore, traditional asthma treatments like as inhalation of corticosteroid, AIT (allergens immunotherapy), and monoclonal antibodies (anti-IgE) may minimize the chance for disease by the causative agent in asthmatics by reducing inflammation and strengthening antiviral defense. The connections between COVID along asthma need to be researched upon more. Infection with a respiratory virus causes up to eighty percent of acute asthma attacks in kids and 50% of similar instances in adults, with Rhinovirus (RV) being the most common cause. (1) CoVs are also seen in asthma exacerbations, with an 8.4 % frequency. Surprisingly, no cases of asthma attacks have been reported as a result of COVID-19. As a result, during the SARS and MERS outbreaks, there seem to be minimal reports of asthma attacks. Such specific events still have to be thoroughly documented. The study's main goal was to find out how common asthma was among COVID-19 participants. COVID-19 was used to examine asthmatic and nonasthmatic patients' clinical features and comorbidities. We also looked at the possibility of being admitted to the hospital as a result of asthma and/or the usage of inhaled corticosteroids.